Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Boris Dominik Juelg, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01AI145801 (BAROUCH, DAN H.) May 12, 2020 - Apr 30, 2024
    NIH
    Ad26 Based Therapeutic Vaccines for HIV
    Role: Co-Principal Investigator
  2. R01AI138790 (JUELG, BORIS DOMINIK) Dec 17, 2018 - Nov 30, 2023
    NIH
    Optimizing HIV-specific T-cell responses by therapeutic vaccination
    Role: Principal Investigator
  3. K08AI106408 (JUELG, BORIS DOMINIK) May 23, 2013 - May 31, 2019
    NIH
    Vaccine induced T-cell protection against SIV infection
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rossignol ED, Dugast AS, Compere H, Cottrell CA, Copps J, Lin S, Cizmeci D, Seaman MS, Ackerman ME, Ward AB, Alter G, Julg B. Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. Cell Rep. 2021 05 25; 35(8):109167. PMID: 34038720.
    Citations: 1     Fields:    Translation:Humans
  2. Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, Kang J, Dayal D, Martin P, Nowak R, Hsieh CL, Feldman J, Julg B, Nilles EJ, Musk ER, Menon AS, Fischer ES, McLellan JS, Schmidt A, Goldberg MB, Filbin M, Hacohen N, Lauffenburger DA, Alter G. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv. 2021 May 12. PMID: 34013263.
    Citations: 2     
  3. Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, Atyeo C, Loos C, Chandrashekar A, McMahan K, Tostanoski LH, Yu J, Gebre MS, Jacob-Dolan C, Li Z, Patel S, Peter L, Liu J, Borducchi EN, Nkolola JP, Souza M, Tan CS, Zash R, Julg B, Nathavitharana RR, Shapiro RL, Azim AA, Alonso CD, Jaegle K, Ansel JL, Kanjilal DG, Guiney CJ, Bradshaw C, Tyler A, Makoni T, Yanosick KE, Seaman MS, Lauffenburger DA, Alter G, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H, Barouch DH. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544. PMID: 33704352.
    Citations: 74     Fields:    Translation:HumansCTClinical Trials
  4. Cizmeci D, Lofano G, Rossignol E, Dugast AS, Kim D, Cavet G, Nguyen N, Tan YC, Seaman MS, Alter G, Julg B. Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. Elife. 2021 04 12; 10. PMID: 33843586.
    Citations: 3     Fields:    Translation:HumansCells
  5. Julg B, Barouch D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. Semin Immunol. 2021 01; 51:101475. PMID: 33858765.
    Citations: 5     Fields:    
  6. Gao A, Chen Z, Amitai A, Doelger J, Mallajosyula V, Sundquist E, Pereyra Segal F, Carrington M, Davis MM, Streeck H, Chakraborty AK, Julg B. Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2. iScience. 2021 Apr 23; 24(4):102311. PMID: 33748696.
    Citations: 2     
  7. Herman JD, Wang C, Loos C, Yoon H, Rivera J, Dieterle ME, Haslwanter D, Jangra RK, Bortz RH, Bar KJ, Julg B, Chandran K, Lauffenburger D, Pirofski LA, Alter G. Functional Antibodies in COVID-19 Convalescent Plasma. medRxiv. 2021 Mar 11. PMID: 33758875.
    Citations:    
  8. Bartsch YC, Loos C, Rossignol E, Fajnzylber JM, Yuan D, Avihingsanon A, Ubolyam S, Jupimai T, Hirschel B, Ananworanich J, Lauffenburger DA, Li JZ, Alter G, Julg B. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. mBio. 2021 03 09; 12(2). PMID: 33688003.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  9. Bartsch YC, Fischinger S, Siddiqui SM, Chen Z, Yu J, Gebre M, Atyeo C, Gorman MJ, Zhu AL, Kang J, Burke JS, Slein M, Gluck MJ, Beger S, Hu Y, Rhee J, Petersen E, Mormann B, Aubin MS, Hasdianda MA, Jambaulikar G, Boyer EW, Sabeti PC, Barouch DH, Julg BD, Musk ER, Menon AS, Lauffenburger DA, Nilles EJ, Alter G. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat Commun. 2021 02 15; 12(1):1018. PMID: 33589636.
    Citations: 28     Fields:    Translation:HumansCells
  10. Rossignol E, Alter G, Julg B. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. J Infect Dis. 2021 02 15; 223(12 Suppl 2):22-31. PMID: 33586772.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  11. Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, Kang J, Edlow AG, Fasano A, Baden LR, Nilles EJ, Woolley AE, Karlson EW, Hopke AR, Irimia D, Fischer ES, Ryan ET, Charles RC, Julg BD, Lauffenburger DA, Yonker LM, Alter G. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021 03; 27(3):454-462. PMID: 33589825.
    Citations: 31     Fields:    Translation:HumansCellsPHPublic Health
  12. Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1). PMID: 33427208.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  13. Offersen R, Yu WH, Scully EP, Julg B, Euler Z, Sadanand S, Garcia-Dominguez D, Zheng L, Rasmussen TA, Jennewein MF, Linde C, Sassic J, Lofano G, Vigano S, Stephenson KE, Fischinger S, Suscovich TJ, Lichterfeld M, Lauffenburger D, Rosenberg ES, Allen T, Altfeld M, Charles RC, Østergaard L, Tolstrup M, Barouch DH, Søgaard OS, Alter G. HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Rep. 2020 12 15; 33(11):108502. PMID: 33326789.
    Citations: 3     Fields:    Translation:HumansCells
  14. Nilles EJ, Siddiqui SM, Fischinger S, Bartsch YC, de Saint Aubin M, Zhou G, Gluck MJ, Berger S, Rhee J, Petersen E, Mormann B, Loesche M, Chen Z, Yu J, Gebre M, Atyeo C, Gorman MJ, Lee Zhu A, Burke J, Slein M, Hasdianda MA, Jambaulikar G, Boyer E, Sabeti P, Barouch DH, Julg BD, Kucharski AJ, Musk ER, Lauffenburger DA, Alter G, Menon AS. Epidemiological and immunological features of obesity and SARS-CoV-2. medRxiv. 2020 Dec 11. PMID: 33200139.
    Citations: 1     
  15. Das J, Devadhasan A, Linde C, Broge T, Sassic J, Mangano M, O'Keefe S, Suscovich T, Streeck H, Irrinki A, Pohlmeyer C, Min-Oo G, Lin S, Weiner JA, Cihlar T, Ackerman ME, Julg B, Deeks S, Lauffenburger DA, Alter G. Mining for humoral correlates of HIV control and latent reservoir size. PLoS Pathog. 2020 10; 16(10):e1008868. PMID: 33048992.
    Citations: 1     Fields:    Translation:HumansCells
  16. Gao A, Chen Z, Segal FP, Carrington M, Streeck H, Chakraborty AK, Julg B. Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2. bioRxiv. 2020 May 15. PMID: 32511339.
    Citations:    
  17. Chen Z, Julg B. Therapeutic Vaccines for the Treatment of HIV. Transl Res. 2020 09; 223:61-75. PMID: 32438074.
    Citations: 1     Fields:    Translation:HumansCells
  18. Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y. A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host Microbe. 2019 Sep 11; 26(3):336-346.e3. PMID: 31513771.
    Citations: 21     Fields:    Translation:AnimalsCells
  19. Yu WH, Su D, Torabi J, Fennessey CM, Shiakolas A, Lynch R, Chun TW, Doria-Rose N, Alter G, Seaman MS, Keele BF, Lauffenburger DA, Julg B. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight. 2019 09 05; 4(17). PMID: 31484826.
    Citations: 4     Fields:    Translation:HumansCells
  20. Julg B, Barouch DH. Neutralizing antibodies for HIV-1 prevention. Curr Opin HIV AIDS. 2019 07; 14(4):318-324. PMID: 31082819.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  21. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268. PMID: 30885693.
    Citations: 70     Fields:    Translation:Humans
  22. Julg B, Alter G. Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity. J Clin Invest. 2018 07 02; 128(7):2743-2745. PMID: 29781815.
    Citations: 1     Fields:    Translation:Humans
  23. Julg B, Barouch DH. HIV-1 Latency by Transition. Immunity. 2017 10 17; 47(4):611-612. PMID: 29045893.
    Citations: 1     Fields:    Translation:HumansCells
  24. Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen TM, Mascola JR, Burton DR, Barouch DH. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. J Virol. 2017 10 15; 91(20). PMID: 28768869.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  25. Julg B, Liu PT, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ, Borducchi EN, Khatiwada S, Kamath M, LeSuer JA, Seaman MS, Schmidt SD, Mascola JR, Burton DR, Korber BT, Barouch DH. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017 Sep 20; 9(408). PMID: 28931655.
    Citations: 69     Fields:    Translation:AnimalsCells
  26. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406). PMID: 28878010.
    Citations: 58     Fields:    Translation:AnimalsCells
  27. Julg B, Pegu A, Abbink P, Liu J, Brinkman A, Molloy K, Mojta S, Chandrashekar A, Callow K, Wang K, Chen X, Schmidt SD, Huang J, Koup RA, Seaman MS, Keele BF, Mascola JR, Connors M, Barouch DH. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol. 2017 08 15; 91(16). PMID: 28539448.
    Citations: 25     Fields:    Translation:AnimalsCells
  28. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 07 28; 535(7613):556-60. PMID: 27338952.
    Citations: 215     Fields:    Translation:HumansCellsCTClinical Trials
  29. Julg B, Alter G. Broadly Neutralizing Antibodies: Magic Bullets against HIV? Immunity. 2016 06 21; 44(6):1253-4. PMID: 27332729.
    Citations: 2     Fields:    Translation:HumansCells
  30. Vojta A, Dobrinic P, Tadic V, Bockor L, Korac P, Julg B, Klasic M, Zoldoš V. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 2016 07 08; 44(12):5615-28. PMID: 26969735.
    Citations: 253     Fields:    Translation:Cells
  31. Jülg B, Barouch DH. Novel immunological strategies for HIV-1 eradication. J Virus Erad. 2015 Oct 01; 1(4):232-6. PMID: 27482421.
    Citations: 3     
  32. Klatt NR, Bosinger SE, Peck M, Richert-Spuhler LE, Heigele A, Gile JP, Patel N, Taaffe J, Julg B, Camerini D, Torti C, Martin JN, Deeks SG, Sinclair E, Hecht FM, Lederman MM, Paiardini M, Kirchhoff F, Brenchley JM, Hunt PW, Silvestri G. Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog. 2014 Aug; 10(8):e1004345. PMID: 25167059.
    Citations: 45     Fields:    Translation:HumansCells
  33. Foley MH, Forcier T, McAndrew E, Gonzalez M, Chen H, Juelg B, Walker BD, Irvine DJ. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One. 2014; 9(2):e87873. PMID: 24551068.
    Citations: 19     Fields:    Translation:HumansCells
  34. Julg B, Poole D, Ghebremichael M, Castilla C, Altfeld M, Sunpath H, Murphy RA, Walker BD. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012; 7(2):e31161. PMID: 22348047.
    Citations: 8     Fields:    Translation:HumansCells
  35. Wright JK, Brumme ZL, Julg B, van der Stok M, Mncube Z, Gao X, Carlson JM, Goulder PJ, Walker BD, Brockman MA, Ndung'u T. Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. J Virol. 2012 Jan; 86(2):1273-6. PMID: 22090116.
    Citations: 4     Fields:    Translation:HumansCells
  36. Varadarajan N, Julg B, Yamanaka YJ, Chen H, Ogunniyi AO, McAndrew E, Porter LC, Piechocka-Trocha A, Hill BJ, Douek DC, Pereyra F, Walker BD, Love JC. A high-throughput single-cell analysis of human CD8? T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest. 2011 Nov; 121(11):4322-31. PMID: 21965332.
    Citations: 75     Fields:    Translation:HumansCells
  37. Streeck H, Kwon DS, Pyo A, Flanders M, Chevalier MF, Law K, Jülg B, Trocha K, Jolin JS, Anahtar MN, Lian J, Toth I, Brumme Z, Chang JJ, Caron T, Rodig SJ, Milner DA, Piechoka-Trocha A, Kaufmann DE, Walker BD, Altfeld M. Epithelial adhesion molecules can inhibit HIV-1-specific CD8? T-cell functions. Blood. 2011 May 12; 117(19):5112-22. PMID: 21403126.
    Citations: 16     Fields:    Translation:HumansCells
  38. Julg B, Moodley ES, Qi Y, Ramduth D, Reddy S, Mncube Z, Gao X, Goulder PJ, Detels R, Ndung'u T, Walker BD, Carrington M. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J Infect Dis. 2011 Mar 15; 203(6):803-9. PMID: 21257739.
    Citations: 24     Fields:    Translation:HumansCells
  39. Chevalier MF, Jülg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, Cutler S, McAndrew E, Jessen H, Pereyra F, Rosenberg ES, Altfeld M, Walker BD, Streeck H. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011 Jan; 85(2):733-41. PMID: 21047960.
    Citations: 105     Fields:    Translation:HumansCells
  40. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker BD, Ebert B, Haining WN. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct; 16(10):1147-51. PMID: 20890291.
    Citations: 238     Fields:    Translation:HumansAnimalsCells
  41. Julg B, Pereyra F, Buzón MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010 Jul 15; 51(2):233-8. PMID: 20550452.
    Citations: 74     Fields:    Translation:HumansCells
  42. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol. 2010 Jun; 84(11):5540-9. PMID: 20335261.
    Citations: 63     Fields:    Translation:HumansCells
  43. Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis. 2009 Sep 15; 49(6):956-64. PMID: 19663693.
    Citations: 14     Fields:    Translation:HumansCells
  44. Julg B, Reddy S, van der Stok M, Kulkarni S, Qi Y, Bass S, Gold B, Nalls MA, Nelson GW, Walker BD, Carrington M, Ndung'u T. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. Cell Host Microbe. 2009 May 08; 5(5):413-5; author reply 418-9. PMID: 19454341.
    Citations: 18     Fields:    Translation:HumansCells
  45. Walley NM, Julg B, Dickson SP, Fellay J, Ge D, Walker BD, Carrington M, Cohen MS, de Bakker PI, Goldstein DB, Shianna KV, Haynes BF, Letvin NL, McMichael AJ, Michael NL, Weintrob AC. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe. 2009 May 08; 5(5):408-10; author reply 418-9. PMID: 19454339.
    Citations: 20     Fields:    Translation:HumansCells
  46. Julg B, Walker BD. The paradox of incomplete CD4+ cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect Dis. 2009 Mar 15; 48(6):795-7. PMID: 19196173.
    Citations:    Fields:    Translation:Humans
  47. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, Rothchild AC, Block BL, Schneidewind A, Koibuchi T, Pereyra F, Allen TM, Walker BD. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009 Apr; 83(7):3138-49. PMID: 19158248.
    Citations: 60     Fields:    Translation:HumansCells
  48. Julg B, Bogner JR. Atriplatrade mark - HIV therapy in one pill. Ther Clin Risk Manag. 2008 Jun; 4(3):573-7. PMID: 18827852.
    Citations: 4     
  49. Jülg B, Elias J, Zahn A, Köppen S, Becker-Gaab C, Bogner JR. Bat-associated histoplasmosis can be transmitted at entrances of bat caves and not only inside the caves. J Travel Med. 2008 Mar-Apr; 15(2):133-6. PMID: 18346250.
    Citations: 9     Fields:    Translation:HumansAnimalsPHPublic Health
  50. Claas GJ, Jülg B, Goebel FD, Bogner J. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. Eur J Med Res. 2007 Feb 26; 12(2):54-60. PMID: 17369118.
    Citations: 7     Fields:    Translation:Humans
  51. Jülg B, Goebel FD. Clinical news from the XVI International AIDS Conference: The attempt of a summing up. Infection. 2006 Oct; 34(5):294-7. PMID: 17033758.
    Citations:    Fields:    Translation:Humans
  52. Jülg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. AIDS. 2006 Jul 13; 20(11):1563. PMID: 16847416.
    Citations: 1     Fields:    Translation:Humans
  53. Jülg B, Goebel FD. Treatment interruption in HIV therapy: a SMART strategy? Infection. 2006 Jun; 34(3):186-8. PMID: 16804667.
    Citations: 3     Fields:    Translation:Humans
  54. Sauter M, Jülg B, Porubsky S, Cohen C, Fischereder M, Sitter T, Schlondorff D, Gröne HJ. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006 Jun; 47(6):1075-80. PMID: 16731304.
    Citations: 16     Fields:    Translation:HumansCells
  55. Schmid H, Mühlbayer D, Röling J, Sternfeld T, Jülg B, Schlattner U, Nelson PJ, Bogner JR, Wallimann T, Goebel FD. Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK. Antivir Ther. 2006; 11(8):1071-80. PMID: 17302377.
    Citations: 1     Fields:    Translation:Humans
  56. Jülg B, Goebel FD. CCR5 antagonists: a new tool in fighting HIV. J HIV Ther. 2005 Dec; 10(4):68-71. PMID: 16519245.
    Citations: 1     Fields:    Translation:HumansCells
  57. Jülg BD, Weidner S, Mayr D. Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. Virchows Arch. 2006 Mar; 448(3):369-74. PMID: 16328350.
    Citations: 6     Fields:    Translation:HumansCells
  58. Jülg B, Goebel FD. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect? Infection. 2005 Oct; 33(5-6):405-7. PMID: 16258878.
    Citations:    Fields:    Translation:HumansCells
  59. Jülg B, Goebel FD. What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy? Infection. 2005 Oct; 33(5-6):408-10. PMID: 16258879.
    Citations: 2     Fields:    Translation:HumansCells
  60. Jülg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS. 2005 Aug 12; 19(12):1332-3. PMID: 16052093.
    Citations: 7     Fields:    Translation:Humans
  61. Jülg B, Goebel FD. HIV genetic diversity: any implications for drug resistance? Infection. 2005 Aug; 33(4):299-301. PMID: 16091906.
    Citations: 5     Fields:    Translation:HumansCells
  62. Jülg B, Goebel FD. Susceptibility to HIV/AIDS: an individual characteristic we can measure? Infection. 2005 Jun; 33(3):160-2. PMID: 15940420.
    Citations: 7     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Juelg's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (240)
Explore
_
Co-Authors (66)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.